Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) CFO Stephen Feider sold 744 shares of Beta Bionics stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $17.00, for a total transaction of $12,648.00. Following the sale, the chief financial officer owned 159,378 shares of the company’s stock, valued at approximately $2,709,426. This represents a 0.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Stephen Feider also recently made the following trade(s):
- On Thursday, November 5th, Stephen Feider sold 382 shares of Beta Bionics stock. The stock was sold at an average price of $17.04, for a total transaction of $6,509.28.
- On Wednesday, September 2nd, Stephen Feider sold 6,675 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25.
Beta Bionics Stock Down 0.5%
NASDAQ BBNX traded down $0.09 during trading hours on Friday, hitting $16.42. The company’s stock had a trading volume of 1,095,375 shares, compared to its average volume of 1,171,084. The stock has a fifty day moving average of $18.47 and a 200 day moving average of $14.86. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The firm has a market capitalization of $892.76 million, a P/E ratio of -8.92 and a beta of 3.44.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last released its earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.01. The firm had revenue of $35.51 million during the quarter. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. On average, analysts predict that Beta Bionics, Inc. will post -2.04 earnings per share for the current year.
Wall Street Analyst Weigh In
BBNX has been the subject of a number of analyst reports. Barclays began coverage on Beta Bionics in a research note on Tuesday, October 6th. They set an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “strong sell” rating in a report on Saturday, October 31st. Robert W. Baird increased their target price on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, William Blair initiated coverage on Beta Bionics in a report on Friday, August 21st. They set a “market perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and an average price target of $23.69.
View Our Latest Stock Analysis on Beta Bionics
Institutional Investors Weigh In On Beta Bionics
Several hedge funds have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in shares of Beta Bionics during the second quarter worth $62,000. The Manufacturers Life Insurance Company bought a new stake in shares of Beta Bionics in the 2nd quarter valued at $172,000. 49 Wealth Management LLC bought a new stake in shares of Beta Bionics in the 3rd quarter valued at $260,000. Ieq Capital LLC bought a new stake in shares of Beta Bionics in the 2nd quarter valued at $229,000. Finally, Quantbot Technologies LP acquired a new stake in Beta Bionics during the 2nd quarter worth $264,000.
About Beta Bionics
Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.
Recommended Stories
- Five stocks we like better than Beta Bionics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
